ULURU Inc. (OTCMKTS:ULUR) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
Entry into a Material Definitive Agreement
On December 15, 2017, ULURU Inc. (the "Company") entered into Lease Agreement (the "Lease Agreement") to which the Company agreed to lease 2,452 square feet of office space in Addison, Texas near, and in lieu of, its previous office. Rent under the Lease Agreement is $1,982 per month, plus pro rata share of operating expenses (estimated at $709 per month). The Lease Agreement is for a two-year term expiring on December 31, 2019.
The foregoing summary of the principal terms of the Lease Agreement is not complete and is qualified in its entirety by the actual terms and conditions of that agreement, a copy of which is being filed herewith.
|
Item 1.02 |
Termination of Material Definitive Agreement |
On December 15, 2017, the Company entered into a Termination of Lease and Release Agreement (the "Termination") with its then existing landlord terminating the Lease dated January 31, 2006, as amended on February 22, 2013 and March 17, 2015. The Termination was coordinated with the new Lease Agreement described in Item 1.01 and involved no early termination penalties or other payments, other the payment of prorated rent for December 2017 by the Company and the partial return and partial rollover of a security deposit.
ULURU Inc. ExhibitEX-10.01 2 ex_10-1.htm LEASE AGREEMENT,…To view the full exhibit click here
About ULURU Inc. (OTCMKTS:ULUR)
ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.